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Efficient Biooxidations Catalyzed by a New Generation of Self-Sufficient
Baeyer–Villiger Monooxygenases
Daniel E. Torres PazmiÇo,[a, b] Anette Riebel,[a] Jon de Lange,[a] Florian Rudroff,[b] Marko D. Mihovilovic,[b] and
Marco W. Fraaije*[a]
Over the last decades industrial interest in oxidative biocataly-
sis has increased significantly. One of the most prominent
enzyme families that catalyze a variety of different oxidations
are Baeyer–Villiger monooxygenases (BVMOs). These biocata-
lysts are part of an exclusive family of flavin-dependent en-
zymes that catalyze the biotransformation of aldehydes and
(a)cyclic ketones to their corresponding esters and lactones.[1]
Additionally, these enzymes are also known for their capability
to oxidize heteroatoms (sulphur, nitrogen, boron) and perform
epoxidation reactions.[2] Type I BVMOs utilize flavin adenine di-
nucleotide (FAD) as cofactor and NADPH as electron donor in
order to activate molecular oxygen (O2) and generate a reac-
tive C4a-peroxyflavin intermediate. This enzyme intermediate
acts similarly to an organic peracid and reacts with the organic
substrate and this results in formation of the oxygenated prod-
uct.[3] BVMOs have been shown to carry out these oxidative re-
actions in a highly regio-, stereo- and enantioselective manner;
this indicates that these enzymes are interesting candidates for
various biocatalytic applications.[4] An obstacle of using BVMOs
in a cost efficient way is the requirement of stoichiometric
amounts of expensive NADPH coenzyme. Several coenzyme re-
generation methods have been explored in the recent years.[5]
The most efficient approach is based on the regeneration of
NADPH by using a two-enzyme system (either as isolated
enzyme or in whole cells).[6]
Typically, NAD(P)+-dependent dehydrogenases are applied
to regenerate the reduced coenzyme at the expense of a
cheaper sacrificial substrate.[7] Phosphite dehydrogenase
(PTDH, EC 1.20.1.1) is an excellent example of such NAD(P)H re-
generating enzymes. This enzyme catalyzes the thermodynami-
cally driven oxidation of phosphite to phosphate by simultane-
ous reduction of NAD(P)+ .[5c,8] We have recently investigated
the utility of PTDH in combination with BVMOs. By covalently
fusing this enzyme to various BVMOs, so-called CRE/BVMOs
were created (CRE; coenzyme regenerating enzyme).[9] Advan-
tages of these bifunctional biocatalysts are that 1) with mini-
mum effort in terms of enzyme production and isolation and
2) maximum simplicity with respect to coenzyme regeneration,
challenging enzymatic oxidations can be performed. The first
generation of these self-sufficient CRE/BVMOs were successful-
ly applied for the bioconversions of a wide variety of sub-
strates by using whole cells, cell-free extracts (CFEs) and puri-
fied enzyme. Interestingly, biooxidations using cell-free extracts
could be performed without addition of NADPH/NADP+ . This
can be explained by the fact that sufficient amounts of coen-
zyme are released for catalysis to occur when the Escherichia
coli cells are ruptured.
However, the activity of the first reported self-sufficient
BVMOs decreased significantly over time due to instability of
the PTDH fusion partner. By a successful combination of site-
directed and random mutagenesis approaches, Zhao and co-
workers have been able to improve the thermostability of
PTDH, as well as its resistance towards organic solvents. In
comparison to the wild-type, this PTDH mutant (18 PTDH)
contained 18 mutations and showed a 7000-fold longer life
time at 45 8C.[10]
In this work we present fusion engineering and biocatalytic
studies of a new generation of self-sufficient BVMOs. In com-
parison to the previous generation, these second generation
self-sufficient CRE2/BVMOs posses 1) a thermostable variant of
PTDH as fusion partner for effective coenzyme regeneration,
2) a codon-optimized PTDH mutant gene for excellent expres-
sion in E. coli,[11] and 3) a histidine purification tag at the free N
terminus of the PTDH partner. In this way, the dehydrogenase
fusion partner is not only exploited for its ability to efficiently
regenerate nicotinamide coenzymes, but also as both expres-
sion and purification tag.[12]
For this study, six representative BVMOs were selected and
fused to the C terminus of the thermostable PTDH variant :
cyclopentanone monooxygenase from Comamonas sp. strain
NCIMB 9872 (CPMO, EC 1.14.13.16),[13] cyclohexanone mono-
oxygenase from Acinetobacter sp. NCIMB 9871 (CHMO, EC
1.14.13.22),[14] 4-hydroxyacetophenone monooxygenase from
Pseudomonas fluorescens ACB (HAPMO, EC 1.14.13.81),[15] ethi-
onamide monooxygenase from Mycobacterium tuberculosis
H37Rv (EtaA, EC 1.14.13.92),[16] phenylacetone monooxygenase
from Thermobifida fusca (PAMO; EC 1.14.13.92) and the M446G
PAMO mutant.[17] Expression levels of all six CRE2/BVMOs in E.
coli TOP10 were excellent (see Supporting Information) and
subsequent purification was performed in a one step process
by using a Ni–NTA column. Even CRE2-CPMO was obtained in
good purity while previous attempts to purify CPMO from a re-
combinant host failed, tentatively due to stability reasons.[13b,c]
The activities and kinetic parameters of the isolated CRE2/
BVMOs were determined using the primary substrates of each
enzyme. In general, the catalytic activities (kcat) and Michaelis–
Menten constants (KM) of the BVMOs fused to the thermostable
PTDH were found to be very similar to those of the nonfused
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enzymes (Table 1). The catalytic efficiency (kcat/KM) of the PTDH
subunit for NADP+ was found to vary between 93 and
1300 mm1 s1, depending on its fusion partner. The variance
in these values may reflect the level of flavin cofactor incorpo-
ration in each fused enzyme and are at the same order of
magnitude compared to the nonfused PTDH variant (kcat/KM=
2.5102 mm1 s1).[10c]
In order to determine the stability of these new CRE2/
BVMOs, activity measurements were carried out at elevated
temperatures. Incubation of CRE2-CHMO at 37 8C resulted in
a decrease in BVMO activity over time (t1=2 , 37 8C=95 min),
whereas no loss in activity was observed for the PTDH subunit
during 24 h. This clearly indicates that the activity and stability
of the dehydrogenase is not affected by the thermal inactiva-
tion of its fusion partner. Incubation of CRE2-PAMO at 50 8C
showed that the PTDH subunit is also suitable for coenzyme
regeneration at elevated temperatures, showing a half-life time
(t1=2 , 50 8C) of 39 h. Additionally, we determined that the PTDH
subunit tolerates methanol as organic cosolvent. The initial
specific activity of the dehydrogenase subunit of CRE2-PAMO
was found to be hardly affected when using up to 40% metha-
nol. In the presence of 30% methanol at 30 8C, a slow decrease
in dehydrogenase activity was observed (t1=2=2 h).
Length and composition of peptide linkers are known to
affect protein stability and domain-domain interactions of
fusion enzymes.[18] All CRE2/BVMOs described above contain a
peptide linker consisting of six amino acids, Ser-Arg-Ser-Ala-
Ala-Gly. In order to determine whether the linker has an effect
on the stability of the fusion between PTDH and a BVMO, we
constructed three additional variants of CRE2-PAMO with dif-
ferent linkers. These variants contained a glycine-rich peptide,
a “nature-preferred” peptide or a single tryptophan as linker.
All four variants of CRE2-PAMO were found to have the same
specific activity and thermostability (see Supporting Informa-
tion). These results indicate that the termini of both enzymes
are sufficiently flexible and solvent-exposed to yield an effec-
tive and thermostable fusion enzyme, regardless of the nature
of the peptide linker between these two subunits.
Previously, we demonstrated that bifunctional CRE/BVMOs
can be also applied for bioconversions using whole cells and
cell-free extracts. Cell-free extract containing CRE-CHMO was
used to catalyze the oxidation of 4-methylcyclohexanone (1) to
the corresponding lactone 2 in the presence of phosphite. The
biotransformation stopped after a reaction time of 6 h, while
less than 40% conversion was achieved (>10 mm substrate
concentration).[9] Performing the same transformation with the
newly created thermostable CRE2-CHMO, resulted in a more
effective oxidation of the substrate (Figure 1).
In contrast to the first generation self-sufficient BVMOs, the
thermostable variant CRE2-CHMO showed no inactivation
within the presented time frame. This resulted in the full con-
version of 5 and 10 mm of ketone 1 within 24 h, yielding
>80% product 2. Despite possible substrate inhibition, 13%
of conversion was achieved by using 30 mm of ketone 1, while
hardly any conversion was observed when CHMO was fused to
the relatively thermolabile PTDH.[9] These results confirm that
the instability of PTDH in the first reported self-sufficient CRE/
BVMOs was the limiting factor for efficient bioconversions.
Additionally, we investigated the biocatalytic activities of
other CRE2/BVMOs in cell-free extract by using bicyclo-
[3.2.0]hept-2-en-6-one 3 as a model substrate. At 24 8C, 5 mm
of bicyclic ketone 3 was efficiently oxidized to the correspond-
ing lactones 4 and 5 (Scheme 1) by both CRE2-CHMO (100%)
and CRE2-CPMO (85%). Only 24% of product formation was
observed with CRE2-PAMO after 24 h. At higher substrate con-
centrations (20 mm), CRE2-CHMO fully converted the bicyclic
Table 1. Kinetic parameters of second-generation self-sufficient BVMOs
(CRE2/BVMOs).
BVMO subunit PTDH subunit
kcat KM, ketone KM, NADPH kcat/KM, NADP+
[s1] [mm] [mm] [mm1 s1]
CRE2-PAMO
2.6 60 3.5 360
(phenylacetone)
CRE2-CHMO
13 5.5 4.0 93
(cyclohexanone)
CRE2-CPMO
1.8 <1.0 <1.0 180
(cyclopentanone)
CRE2-HAPMO
12 7.8 8.3 610
(4-hydroxyacetophenone)
CRE2-EtaA
0.1 1300 >120 690
(phenylacetone)
CRE2-PAMOM446G
1.8 2500 <2.0 1300
(benzaldehyde)
Figure 1. Baeyer–Villiger oxidation of 4-methylcyclohexanone 1 by CFE of E.
coli TOP10 expressing CRE2-CHMO in the presence of 100 mm phosphite at
24 8C. No coenzyme was added.
Scheme 1. Baeyer–Villiger oxidation of bicyclo[3.2.0]hept-2-en-6-one 3.
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ketone 3 within 24 h. On the other hand, hardly any conver-
sion was observed with CRE2-CPMO; this indicates that the
CPMO subunit suffers from substrate inhibition. The oxidation
rate of ketone 3 by CRE2-PAMO was found to increase propor-
tionally to the substrate concentration, as similar conversion
percentages were obtained by using 5 and 20 mm of substrate.
This latter observation is in agreement with the low affinity of
PAMO towards this bicyclic compound (KM=15 mm).
[17a]
Moreover, we studied the biooxidation of bicyclo[3.2.0]hept-
2-en-6-one at elevated temperatures. In order to stabilize the
BVMO subunit to some extent, we supplemented the reaction
mixture with 10 mm FAD. Despite the moderate thermostability
of the CHMO subunit (t1=2, 37 8C=95 min), CRE2-CHMO was still
able to fully convert 5 mm of bicyclic ketone within 3 h at
37 8C. However, at higher temperature (50 8C) the bifunctional
enzyme was inactivated within 20 min resulting in a rather
poor conversion (21%). CRE2-PAMO showed a higher catalytic
activity at elevated temperatures compared to the reaction
performed at 24 8C. Even at 50 8C the fusion enzyme was still
active; this indicates that regeneration of NADPH is possible
under these conditions. Unfortunately, hardly any conversion
was observed using CRE2-CPMO at 37 8C and 50 8C. This is in
agreement with the literature which indicates that CPMO is a
labile biocatalyst.[13b,c]
In this contribution we report on the design, production and
evaluation of a new generation of self-sufficient Baeyer–Villiger
monooxygenases: CRE2/BVMOs. In comparison to the previous
generation, these newly designed bifunctional enzymes con-
tain a multiple mutant of PTDH which has been shown to dis-
play a high thermostability.[10c] In addition, the gene of this
PTDH mutant was codon-optimized for expression in E. coli.
Furthermore, CRE2/BVMOs contain a polyhistidine affinity-tag
at their N terminus that facilitates purification of all bifunction-
al biocatalysts. The purified self-sufficient BVMOs displayed
similar kinetic parameters as the nonfused enzymes; this sug-
gests that the properties of these enzymes are hardly affected
upon fusion. As expected, their PTDH subunit showed higher
(thermo)stability than the dehydrogenase subunit of the first
reported self-sufficient BVMOs. Furthermore, these new bifunc-
tional enzymes could be applied as cell-free extracts for con-
version of several ketones without loss of activity. Even at ele-
vated temperatures, sufficient regeneration of NADPH took
place for the enzyme-catalyzed Baeyer–Villiger oxidation to
occur. Based on these results we can conclude that with the
thermostable variant of PTDH as fusion-CRE partner, stable and
effective self-sufficient BVMOs can be created that have the
potential to be applied in biocatalytic processes.
Experimental Section
General methods: Unless otherwise noted, all chemicals and en-
zymes were obtained from ACROS Organics, Sigma–Aldrich, Jlich
Fine Chemicals (Jlich, Germany), Riedel-de Han Fine Chemicals
(Seelze, Germany), Roche Applied Sciences, New England Biolabs
and Finnzymes (Espoo, Finland) and used without further purifica-
tion. Oligonucleotide primers were obtained from Sigma Genosys.
DNA sequencing was done at GATC Biotech AG (Konstanz, Germa-
ny). Synthesis of the 18x ptxD gene was performed by DNA 2.0.
The synthetic gene encoding the 18-fold mutant of phosphite de-
hydrogenase from Pseudomonas stutzeri WM88 was designed by
using Gene Designer.[11] The nucleotide sequence of this mutant
was optimized using this software tool for optimal codon usage in
E. coli. In addition, a His6 tag was added upstream of the synthetic
gene to facilitate enzyme purification. Furthermore, recognition
sites for the restriction enzymes NcoI, NdeI and XhoI were intro-
duced to facilitate cloning, whereas PvuII and HindIII restriction
sites were avoided.
Cloning strategy: For the creation of pCRE2-PAMO, a modified
pBAD vector was used in which the NdeI site was replaced by the
original NcoI site. Subsequent cloning of the gene encoding the
18x mutant of phosphite dehydrogenase with N-terminal His-tag
(from pJ36/18x PTDH) and the pamO gene by using NcoI/XhoI,
respectively PvuII/HindIII, yielded expression vector pCRE2-PAMO.
Expression vectors pCRE2-CHMO, pCRE2-CPMO, pCRE2-HAPMO
and pCRE2-EtaA were created by subcloning, respectively, the
chnB, cpnB, hapE and etaA genes.[13–16] Expression vector pCRE2-
PAMOM446G was created using the QuikChange Site-Directed Muta-
genesis Kit of Strategene with pCRE2-PAMO as template and fol-
lowing the recommendations of the manufacturer.
Overexpression and fusion enzyme purification: All self-sufficient
BVMOs were overexpressed in E. coli TOP10 by using Terrific Broth
(TB) medium containing ampicillin (50 mgmL1) and l-arabinose
(0.02% w/v). CRE2-PAMO (and the linker variants), CRE2-PAMOM446G
and CRE2-CHMO were overexpressed at 24 8C during 36 h. CRE2-
CPMO, CRE2-HAPMO and CRE2-EtaA were overexpressed at 17 8C
during 48 h. Thereafter, cells were harvested, washed and resus-
pended in Tris/HCl (50 mm, pH 7.5) containing FAD (10 mm). Cells
expressing CRE2-CHMO were resuspended in Tris/HCl (50 mm,
pH 7.5) supplemented with DTT (0.5 mm) and glycerol (10% w/v),
whereas cells expressing CRE2-EtaA were resuspended in Tris/HCl
(50 mm, pH 7.5) supplemented with b-mercaptoethanol (1 mm),
NaN3 (1 mm), KCl (100 mm), glycerol (10% w/v) and Triton X-100
(1% v/v). All further steps were carried out at 4 8C. After breaking
the cells by ultrasonication and removing cell debris by centrifuga-
tion, fusion enzymes were purified using Ni–NTA (2 mL) column.
After purification, excess of imidazole was removed using an
Econo-PAC 10DG desalting column (BioRad). The fusion enzymes
were concentrated by ultrafiltration and stored at 80 8C.
Determination of kinetic parameters of isolated fusion enzymes:
Activities of purified enzymes were determined spectrophotometri-
cally by monitoring increase or decrease of NADPH in time at 340
(eNADPH=6.2 mm
1 cm1) or 370 nm (eNADPH=2.7 mm
1 cm1). The re-
action mixture (1 mL) typically contained Tris/HCl (50 mm, pH 7.5),
coenzyme (100 mm), ketone (2 mm) or Na2HPO3 (5 mm) and
enzyme (0.05–1 mm) at 25 8C. The following ketones were used:
phenylacetone for CRE2-PAMO and CRE2-EtaA, cyclohexanone for
CRE2-CHMO, cyclopentanone for CRE2-CPMO, 4-hydroxyacetophe-
none for CRE2-HAPMO and benzaldehyde for CRE2-PAMOM446G.
Kinetic parameters were obtained by fitting the obtained data as
described previously.[19] Thermostability of the enzymes was deter-
mined by incubating approximately 30 mm enzyme at 37 or 50 8C,
after which their remaining activity was determined at 25 8C using
saturating substrate concentrations.
General protocol for cell-free extract (CFE) biotransformations:
Fresh TB medium (0.2 or 0.5 L) containing ampicillin (50 mgmL1)
was inoculated with 1% of an overnight preculture of recombinant
E. coli TOP10 overexpressing CRE2-PAMO, CRE2-CHMO or CRE2-
CPMO in a baffled Erlenmeyer flask (1 or 2.5 L). l-Arabinose (final
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concentration 0.02% (w/v)) was added and the culture was incu-
bated at 120 rpm at 24 8C on an orbital shaker for 24 or 40 h, de-
pending on the total volume. Cells were harvested by centrifuga-
tion (6000g, 10 min, 4 8C, Sigma 3 K30 centrifuge, rotor 19777). The
cell pellets were resuspended in PBS buffer (10 mm, pH 7.4, double
volume of cells) containing PMSF (0.1%, v/v) and disintegrated by
ultrasonication. Cell debris was removed by centrifugation
(15000g, 20 min, 4 8C, Sigma 6 K15 centrifuge, rotor 372/C). The
CFE was divided into aliquots (0.5 mL) and stored at 20 8C until
needed. Protein concentration of the cell-free extract was estimat-
ed by Bradford method using Protein Assay (Bio-Rad). Biotransfor-
mations using CFE were realized in either regular 96-well or 12-
well plates. The total reaction volume in each well was 150 mL or
2 mL, and contained protein (approximately 8 mgmL1) and
Na2HPO3 (100 mm, final concentrations). Substrate inhibition stud-
ies were performed by using 4-methylcyclohexanone (5–30 mm).
Other biotransformations were carried out by using racemic
bicyclo[3.2.0]hept-2-en-6-one as substrate (5 or 20 mm). The mix-
ture was incubated at 700 rpm at 24 8C in a multi-well plate incu-
bator (Heidolph Titramax 1000, Heidolph Instruments, Schwabach,
Germany). All biotransformations carried out at elevated tempera-
tures (37 and 50 8C) were supplemented with FAD (10 mm, final
concentration). Samples were taken in regular intervals, extracted
with ethylacetate including internal standard (1 mm of methyl ben-
zoate) and analyzed by gas chromatography.[20]
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